NCT05518851 TreAtments and outComes in paTients With prImary CutAneous Lymphoma
| NCT ID | NCT05518851 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Primary Cutaneous Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-08-01 |
| Primary Completion | 2032-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-08-01 with a primary completion date of 2032-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In order to further improve the diagnosis and treatment level of primary cutaneous lymphoma in China, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for primary cutaneous lymphoma to systematically and effectively understand the current treatment status of patients with primary cutaneous lymphoma, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of primary cutaneous lymphoma and help patients with primary cutaneous lymphoma.
Eligibility Criteria
Inclusion Criteria: * Patients from the participatin medical centers that has passed the data review of the National Clinical Center for Skin and Immune Diseases. * Patients with a definitive pathological diagnosis of primary cutaneous lymphoma by skin biopsy. Exclusion Criteria: * Patients who fail to provide informed consent form. * Patients who cannot complete the questionnaire independently or under the guidance of investigators.
Contact & Investigator
Yang Wang, MD
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT05518851 clinical trial?
This trial is open to participants of all sexes, studying Primary Cutaneous Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05518851 currently recruiting?
Yes, NCT05518851 is actively recruiting participants. Contact the research team at yangwang_dr@bjmu.edu.cn for enrollment information.
Where is the NCT05518851 trial being conducted?
This trial is being conducted at Beijing, China, Guandong, China, Nanjing, China, Jinan, China and 1 additional location.
Who is sponsoring the NCT05518851 clinical trial?
NCT05518851 is sponsored by Peking University First Hospital. The principal investigator is Yang Wang, MD at Peking University First Hospital. The trial plans to enroll 3,000 participants.